|Application ||WB, E|
|Calculated MW||46723 Da|
|Antigen Region||127-153 aa|
|Other Names||Leucine-rich repeat protein 1, 4-1BB-mediated-signaling molecule, 4-1BBlrr, LRR-repeat protein 1, LRR-1, Peptidylprolyl isomerase-like 5, LRR1, PPIL5|
|Target/Specificity||This PPIL5 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 127-153 amino acids from the Central region of human PPIL5.|
|Format||Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein A column, followed by peptide affinity purification.|
|Storage||Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.|
|Precautions||PPIL5 Antibody (Center) is for research use only and not for use in diagnostic or therapeutic procedures.|
|Function||May negatively regulate the 4-1BB-mediated signaling cascades which result in the activation of NK-kappaB and JNK1. Probable substrate recognition subunit of an ECS (Elongin BC- CUL2/5-SOCS-box protein) E3 ubiquitin-protein ligase complex which mediates the ubiquitination and subsequent proteasomal degradation of target proteins.|
|Tissue Location||Ubiquitous. Maximal expression was seen in the heart and skeletal muscle and minimal expression seen in the kidney|
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
The protein encoded by this gene contains a leucine-rich repeat (LRR). It specifically interacts with TNFRSF9/4-1BB, a member of the tumor necrosis factor receptor (TNFR) superfamily. Overexpression of this gene suppresses the activation of NF-kappa B induced by TNFRSF9 or TNF receptor-associated factor 2 (TRAF2), which suggests that this protein is a negative regulator of TNFRSF9-mediated signaling cascades. At least three alternatively spliced transcript variants encoding distinct isoforms have been observed.
Jang, L.K., et al. Mol. Cells 12(3):304-312(2001)
If you have any additional inquiries please email technical services at firstname.lastname@example.org.